Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-08-05

Clinical Trial Update: Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Teneligliptin (MP-513) to placebo in Type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Teneligliptin (Teneligliptin)

Snippet

Sponsor: Handok Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED